Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03303898
Other study ID # 17-AOI-04
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 10, 2017
Est. completion date September 1, 2021

Study information

Verified date March 2022
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases. Leishmaniasis is parasitic reticulo-endotheliosis, the pathogenic agent of which is a flagellated protozoan belonging to the genus Leishmania. It is estimated that there are about 2 million new cases per year. Effective treatments against visceral leishmaniasis are few and resistance problems appear. To date, only a canine vaccine is available protecting dogs from the development of canine leishmaniasis to L. infantum. In man, in parallel clinical cases, leishmaniasis is characterized by a large number of asymptomatic carriers. This is the case in the Alpes-Maritimes where 50% of the inhabitants of the hinterland of Nice are carriers of the parasite. the investigators wish to study the protective immune response to the parasite and more particularly to the asymptomatic carriers. Indeed, these patients were infected with the parasite and did not develop the disease. Understanding the protective immune response in these patients against the parasite is therefore paramount in the development of a human leishmaniasis vaccine. For this purpose, the investigator wants to make an ex vivo study of the immune response of lymphocytes coming from asymptomatic carriers after stimulation by Leishmania vaccine peptides. It also wants to describe the immune response, after stimulation by these peptides, in the lymphocytes of subjects asymptomatic carriers and lymphocytes from subjects not infected with the parasite and comparing them. This study is unicentric and non-randomized. It wishes to recruit 20 asymptomatic carriers of L. Infantum and 10 uninfected subjects. They will be selected from our database. A simple blood sample will be taken. After verification by quantitative PCR and western blotting of their status towards leishmaniasis, the team will divide them into two groups (asymptomatic or healthy). Then the blood samples will be sent to the team of Jean Loup Lemesre of the Laboratory INTERTRYP - UMR177 of the IRD in Montpellier. ELISPOT analysis and assay of cytokines and proteases to describe the immune response of the two groups and to compare them. In addition, cell typing will be performed by flow cytometry to determine the type of lymphocytes involved in the immune response against Leishmania peptides. HLA typing will also be performed to validate the HLA coverage of the peptides tested. Finally, an analysis of the transcryptome will be carried out, which will allow to identify the differential expression of genes and metabolic pathways involved in the immune response and thus to understand how asymptomatic people can control the infection.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 1, 2021
Est. primary completion date November 10, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria for asymptomatic careers - Male and Female - Age between 18 and 80 years - PCR and western blot positive to L. Infantum (these exams will be redone as part of the study). - Signature of informed consent - Affiliation to a social security scheme Exclusion Criteria: - Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation. - Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice. - Persons under guardianship Inclusion Criteria for healthy patient - Male or Female - Age between 18 and 80 years - PCR and western blot negative Leishmania (these exams will be redone as part of the study). - Signature of informed consent - Affiliation to a social security scheme Exclusion Criteria: - Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation. - Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice.

Study Design


Intervention

Procedure:
Blood sampling
sampling of 7 blood tubes

Locations

Country Name City State
France Nice Hospital Nice

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary immune response of lymphocytes from asymptomatic carriers decription of immune response of lymphocytes from asymptomatic carriers after stimulation by Leishmania vaccine peptides in ex vivo ELIPSPOT: Presence or absence of immune response. 15 months
See also
  Status Clinical Trial Phase
Terminated NCT01140191 - Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis Phase 2
Completed NCT03999970 - A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol N/A
Completed NCT00111553 - Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis Phase 1
Recruiting NCT03762070 - Evaluation of a Diagnostic Device, CL Detectâ„¢ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
Completed NCT02894008 - A Study of a New Leishmania Vaccine Candidate ChAd63-KH Phase 2
Recruiting NCT05094908 - Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis Phase 1
Completed NCT01083576 - Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Phase 2
Completed NCT03445897 - Miltefosine Plus IL Pentamidine for Bolivian CL Phase 2
Withdrawn NCT04072874 - Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis. Phase 1/Phase 2
Completed NCT01032382 - Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Phase 2
Completed NCT00480883 - Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol N/A
Recruiting NCT05708625 - Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis Phase 3
Completed NCT04841239 - Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis N/A
Completed NCT00469495 - Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis N/A
Completed NCT03294161 - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Phase 2
Completed NCT04888130 - Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
Completed NCT03969134 - A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL Phase 2
Completed NCT03096457 - Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Phase 2/Phase 3
No longer available NCT01641796 - Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis
No longer available NCT00508963 - Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis